Background The dynamic changes of lymphocyte subsets and cytokines profiles of patients
with novel coronavirus disease (COVID-19) and their correlation with the disease severity …

Long-term antibody responses and neutralizing activities in response to SARS-CoV-2
infection are not yet clear. Here we quantify immunoglobulin M (IgM) and G (IgG) antibodies …

Major advances have been made in understanding the dynamics of humoral immunity briefly
after the acute coronavirus disease 2019 (COVID-19). However, knowledge concerning …

While the immunogenicity of inactivated vaccines against coronavirus disease 2019 (COVID‐19)
has been characterized in several well-conducted clinical trials, real-world evidence …

Coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2 infection, has become a
major global public health threat. Although significant advances have been made in …

Background The current desirable endpoint of treatment against chronic hepatitis B virus
infection (cHBV) is to achieve a functional cure, which is defined as HBsAg loss (sAg-L) with or …

Severe fever with thrombocytopenia syndrome virus (SFTSV), the causative agent of a febrile
human disease, was first identified from central and eastern provinces in China, and later …

COVID-19, caused by SARS-CoV-2, has resulted in hundreds of millions of infections and
millions of deaths worldwide. Preliminary results exhibited excellent efficacy of SARS-CoV-2 …

Severe fever with thrombocytopenia syndrome (SFTS) is an emerging infectious disease
with high mortality (12%–30%). The mechanism by which the SFTS bunyavirus (SFTSV) …

This study longitudinally evaluated the immune response in individuals over a year after
receiving three doses of an inactivated SARS‐CoV‐2 vaccine, focusing on reactions to Omicron …